6-14-10 Small Cap Market Update from Express IR

Stocks Loose Ground After Greek Downgrade

Stocks closed slightly lower on Monday on the Dow Jones Industrial Average (10,190.89 , down 20.18) and the S&P 500 (1,089.63, down 1.97) as the latest downgrade of Greece’s debt weighed on investors. In recent weeks stocks have been overly sensitive to fluctuations in the currency markets. The euro, which has gained ground against the dollar, retreated from its daily highs and helped push major stock indexes lower after Moody’s Investors Service cut Greece’s government-bond ratings to Ba1, which is a junk-grade rating. The Nasdaq Composite Index posted a slight gain to close at 2,243.96 for a gain of 0.36.

On a positive note about the global recovery on Monday, St. Louis Fed President James Bullard, speaking in Tokyo, said he expects an Asian-led world economic recovery to continue, and that he didn’t see evidence of a Chinese bubble. Nor did he think the European debt crisis was poised to derail the economic recovery. As optimism built, demand for safe-haven assets slackened. Treasuries slipped, pushing the yield on the 10-note up to 3.290%. Gold futures also declined, while crude-oil prices climbed near $75 a barrel.

Company	Symbol	Last		Chg	%Chg	Open	High	Low	Vol
Eagleford Energy I	EFRDF	0.75		0.70	1,400.00%	0.75	0.75	0.75	7.75 k
Monkey Rock Group	MKRO	2.24		1.73	339.22%	2.24	2.24	2.24	100
Vibe Records Inc.	VBRE	0.05		0.038	316.67%	0.02	0.069	0.02	347.7 k
Ubiquitech Softwar	UBQU	0.20		0.135	207.69%	0.20	0.20	0.20	5.0 k
CNC Development Lt	CDLWF	0.15		0.10	200.00%	0.15	0.15	0.15	200
Halo Companies Inc.	HALN	1.40		0.90	180.00%	1.40	1.40	1.40	640
International Mone	ITNM	1.25		0.69	123.21%	1.25	1.25	0.30	2.45 k
China Forestry inc.	CHFY	0.02		0.0105	110.53%	0.02	0.02	0.02	27.5 k
Visualant Inc.	VSUL	0.40		0.20	100.00%	0.25	0.40	0.25	29.0 k
Global Ink Supply	GBIK	0.50		0.25	100.00%	0.51	0.51	0.49	10.0 k

Monday’s Newsmakers:

Multi-Title, Multi-Year Agreement for Blockbuster Franchise Extends Through 2012
Jun. 14, 2010 (PR Newswire)

LOS ANGELES, June 14 /PRNewswire-FirstCall/ — Activision Publishing, Inc. ATVI and Microsoft MSFT announced today a multi-year agreement that will continue to bring Call of Duty® game add ons and map packs first to Xbox LIVE online entertainment network. The news was revealed today to a capacity-crowd at Microsoft’s Xbox 360 E3 press conference in Los Angeles. The agreement which began in 2009 now extends for all add ons and map packs from the mega-blockbuster Call of Duty® franchise through 2012, including Call of Duty®: Black Ops, the follow up to the largest entertainment launch in history and one of the most-anticipated titles of the year set for release Nov. 9th.

“Our Treyarch Studio is doing something special with Call of Duty: Black Ops, which is why we’re thrilled to announce this Xbox LIVE agreement,” said Philip Earl, Executive Vice President & General Manager of Activision’s Call of Duty Business Unit. “This agreement reflects our shared and continued focus on creating the most compelling and exciting content releases for fans around the world.”

With billions of hours logged online, Call of Duty titles consistently rank atop Xbox LIVE’s most-played charts, making it the largest Call of Duty community of any entertainment system.

“With 25 million members, Xbox LIVE is the industry’s premier online gaming service that establishes the best in cooperative and multiplayer online play for blockbuster franchises like Call of Duty,” said Marc Whitten, Microsoft’s corporate vice president of Xbox LIVE. “With the release of game add ons and map packs coming first to Xbox 360, Xbox LIVE is the place to play Call of Duty for years to come.”

For more information about Call of Duty: Black Ops, visit www.CallofDuty.com/BlackOps.

About Activision Publishing, Inc.

Headquartered in Santa Monica, California, Activision Publishing, Inc. is a leading worldwide developer, publisher and distributor of interactive entertainment and leisure products.

Activision maintains operations in the U.S., Canada, the United Kingdom, France, Germany, Ireland, Italy, Sweden, Spain, Norway, Denmark, the Netherlands, Australia, South Korea, China and the region of Taiwan. More information about Activision and its products can be found on the company’s website, www.activision.com.

Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
Jun. 14, 2010 (Business Wire)

Genzyme Corporation GENZ announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

The FDA’s Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Under Fast Track designation, alemtuzumab for MS is eligible for Priority Review and the FDA may consider for review portions of the marketing application before the submission of a New Drug Application (NDA) is completed.

“We are extremely pleased that our alemtuzumab development program has been assigned Fast Track status, and look forward to working closely with the FDA to expedite the program’s review process,” said Henri Termeer, Genzyme’s chairman and chief executive officer. “Alemtuzumab is a potentially transformative therapy for the treatment of multiple sclerosis, and an important part of our future.”

Alemtuzumab for the treatment of MS is currently being evaluated in two pivotal multi-center, multi-national trials, known as CARE-MS SM (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis). The company’s CARE-MS I Phase 3 trial is a randomized study comparing alemtuzumab to the approved therapy Rebif (high-dose interferon beta-1a) in early, relapsing-remitting multiple sclerosis (RRMS) patients who have received no prior therapy. The second Phase 3 trial, CARE-MS II, is comparing alemtuzumab to Rebif in RRMS patients who had active disease while on other MS therapies.

Both trials are fully enrolled and data are expected to be available in 2011.

About Campath® (alemtuzumab)

Campath® is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and for whom fludarabine combination therapy is not appropriate. The product was launched in its oncology indication in 2001 in the US, where it is marketed as Campath®, and in Europe, where it is named MabCampath®.

Campath for B-CLL has a boxed warning that includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

Express IR (XIR) is an electronic publication, and is for informational purposes only. The stocks profiled by XIR are only company profiles and are not intended to be and should not be accepted by you as recommendations to buy or sell in these securities. These profiles are compiled from publicly available sources. Our sources include, but are not limited to, online research, company profiles, member suggestions, magazines, newspapers, analyst suggestions, broker recommendations, contact with the company, company rumors, press releases and other similar information sources. All profiles are based on information that is accessible by the public. Investing in stocks involves risk. XIR is not and does not hold itself out to be a registered broker or dealer or other licensed securities professional. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. For compensation and complete disclaimer click here.

Contact: Ralph Sharp rsharp@expressir.com

Related posts

• No related posts.